Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged \> 18~* Histologically confirmed epithelial ovarian, peritoneal, or fallopian tube cancer, and uterine papillary serous carcinomas (UPSC), and gynecologic malignant mixed müllerian tumors (MMMTs).~* Must have had prior platinum or platinum based therapy.~* Eastern Cooperative Oncology Group (ECOG) status 0-1.~* Platinum resistant or refractory disease within 6 months of completing or while receiving a platinum and taxane containing regimen~* Measurable disease~* Adequate bone marrow and hematological function.~* Must have recovered from acute toxicity from prior treatment~* Prior treatment with an anti-angiogenic agent is not an exclusion criterion.~* No prior GI perforation, or GI obstruction or involvement of the bowel on imaging~* Known hypersensitivity to Cremophor EL. However, participants are eligible if they have had a prior paclitaxel reaction, but subsequently tolerated the drug at rechallenge.~* No patients receiving other investigational therapy for the past 30 days before dosing.~Exclusion Criteria:~* More than 3 prior lines of chemotherapy for recurrent cancer.~* History of other active malignancy, other than superficial basal cell and superficial squamous cell, or carcinoma in situ of the cervix within last 2 years.~* Life expectancy of less than 3 months~* CTC Grade 1 or greater neuropathy (motor or sensory) from comorbidity other than prior taxane exposure, such as diabetes.~* Inadequately controlled hypertension or prior history of hypertensive crisis or hypertensive encephalopathy.~* New York Heart Association (NYHA) Grade II or greater congestive heart failure.~* History of myocardial infarction or unstable angina within 6 months prior to study Day 1.~* History of stroke or transient ischemic attack within 6 months prior to Day 1.~* Known CNS disease, except for treated brain metastasis~* Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.~* History of hemoptysis (1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1.~* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VB-111 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).